样式: 排序: IF: - GO 导出 标记为已读
-
Aortic insufficiency in the patient on contemporary durable left ventricular assist device support: Comment. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-01 Hinpetch Daungsupawong,Viroj Wiwanitkit
-
Can sinoatrial reinnervation improve survival after heart transplantation? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-16 Anders H Christensen
-
Apixaban plasma levels in patients with HeartMate 3 support. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-15 Charlotte J Van Edom,Bjorn Cools,Walter Droogné,Steven Jacobs,Van Puyvelde Joeri,Dirk Vlasselaers,Thomas Vanassche,Bart Meyns
BACKGROUND Apixaban is increasingly used instead of vitamin K antagonists (VKAs) for long-term anticoagulation during HeartMate 3 (HM3) support. However, data on its pharmacokinetics in this context is lacking. We present real-world data on apixaban levels and outcomes in adult and pediatric HM3 patients, and evaluate our dosing strategy based on plasma sampling. METHODS Since June-2023, all new HM3
-
Advancing Patient-Centered Metrics for Heart Transplantation: The Role of Days Alive and Outside the Hospital. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-15 J'undra N Pegues,Reem M Fawaz,Kinka M Kimfon,Hechuan Hou,Pierre-Emmanuel Noly,Thomas M Cascino,Robert B Hawkins,James W Stewart Ii,Keith Aaronson,Jennifer Cowger,Francis D Pagani,Donald S Likosky,
BACKGROUND Heart transplantation (HT) survival and waitlist times are established outcome metrics. Patient-centered HT outcomes are insufficiently characterized. This study evaluates the role of days alive and outside the hospital (DAOH) as a candidate patient-centered HT performance measure. METHODS The study cohort included Medicare beneficiaries undergoing HT (July 2008-December 2017). The percent
-
Navigating Surgical Risks: The Impact of BMI Outliers on Pulmonary Endarterectomy Outcomes. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-15 Olaf Mercier
-
Factors associated with waitlist clinical deterioration among United States lung transplant recipients under the continuous distribution system. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-11 Tatenda G Mupfudze,Chelsea J Hawkins,Samantha Weiss,Rebecca R Goff,Grace R Lyden,Erika D Lease,Matthew Hartwig,Maryam Valapour
BACKGROUND Lung continuous distribution (CD), implemented on March 9, 2023, changed the calculation and relative importance of medical urgency and posttransplant survival in prioritizing candidates for transplant. We aimed to identify factors associated with waitlist clinical deterioration and change in expected posttransplant survival from listing to transplant in the current system. METHODS We used
-
Xenotransplantation of Mitochondria: A Novel Strategy to Alleviate Ischemia-Reperfusion Injury during Ex Vivo Lung Perfusion. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-11 Nicholas B Bechet,Aybuke Celik,Margareta Mittendorfer,Qi Wang,Tibor Huzevka,Gunilla Kjellberg,Embla Boden,Gabriel Hirdman,Leif Pierre,Anna Niroomand,Franziska Olm,James D McCully,Sandra Lindstedt
Ischemia-reperfusion injury (IRI) plays a crucial role in the development of primary graft dysfunction (PGD) following lung transplantation. A promising novel approach to optimize donor organs before transplantation and reduce the incidence of PGD is mitochondrial transplantation. In this study, we explored the delivery of isolated mitochondria in 4 hour ex vivo lung perfusion (EVLP) before transplantation
-
Risk assessment models and survival in pulmonary arterial hypertension: a SPAHR analysis. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-11 Clara Hjalmarsson,Tanvee Thakur,Tracey Weiss,Erik Björklund,Joanna-Maria Papageorgiou,Göran Rådegran,Stefan Söderberg,Håkan Wåhlander,Dominik Lautsch,Barbro Kjellström
BACKGROUND Multicomponent improvement (MCI) is a novel endpoint for predicting survival in patients with pulmonary arterial hypertension (PAH), included in the sotatercept clinical program. For the first time, we investigated the prognostic value of MCI, ESC/ERS 4-strata risk (4SR) assessment, and the non-invasive French risk stratification score (FRS), for predicting survival in PAH patients in Sweden
-
Impact of donor age ≥65 years on graft survival in large lung transplant cohorts. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-11 Andrei M Darie,Bronwyn J Levvey,Helen V Shingles,Miranda A Paraskeva,Kovi Levin,Samantha L Ennis,Michael Perch,Glen P Westall,Prof Gregory I Snell
BACKGROUND Although the demand for allografts continuously surpasses the supply, the majority of lungs offered for transplant are declined based on various factors, including donor age. This in turn sustains the wait-list mortality of patients with end-stage pulmonary disease. METHODS In this single center, observational cohort study we investigated the impact of donor age on graft survival. We additionally
-
Towards Early Prediction of Chronic Allograft Dysfunction using Molecular Biomarkers. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-08 Peter T Bell,Daniel C Chambers
-
Optimized surveillance frequency for low bone mineral density (BMD) screening using dual energy X-ray absorptiometry (DXA) in patients after lung transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-07 Ronnie Sebro,Mahmoud Elmahdy
BACKGROUND Approximately 2700 lung transplants are performed annually in the United States. These patients are at increased risk of developing low bone mineral density (osteopenia/osteoporosis) and subsequent osteoporosis-related fractures. Dual energy x-ray absorptiometry (DXA) is the most common method used for screening for low BMD, however, the optimal surveillance frequency for low BMD using DXA
-
A Systematic Review of Reporting and Handling of Missing Data in Observational Studies Using the UNOS Database. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-07 William L Baker,Timothy Moore,Eric Baron,Michelle Kittleson,William F Parker,Abhishek Jaiswal
BACKGROUND Missing data can undermine a registry's ability to draw valid inferences by decreasing study power and introducing bias. We evaluated how missing data are reported and addressed in observational studies of adult heart transplantation (HT) recipients using the United Network for Organ Sharing (UNOS) database. METHODS We conducted a systematic literature search of Medline from January 1st
-
Periodic administration of Levosimendan as a Bridge to Transplant Potiusque Sero Quam Nunquam. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-06 Daniele Masarone,Luigi Falco,Angelo Caiazzo,Claudio Marra,Emilio di Lorenzo
-
Long Short-Term Memory Algorithm for Personalized Tacrolimus Dosing: A Simple and Effective Time Series Forecasting Approach Post-Lung Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-05 Haruki Choshi,Kentaroh Miyoshi,Maki Tanioka,Hayato Arai,Shin Tanaka,Kazuhiko Shien,Ken Suzawa,Mikio Okazaki,Seiichiro Sugimoto,Shinichi Toyooka
BACKGROUND Management of tacrolimus trough levels influences morbidity and mortality after lung transplantation. Several studies have explored pharmacokinetic and artificial intelligence models to monitor tacrolimus levels. However, many models depend on a wide range of variables, some of which, like genetic polymorphisms, are not commonly tested for in regular clinical practice. This study aimed to
-
Could Emulated Trials Play a Key Role in Cardiogenic Shock Trials? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-04 Aurore Ughetto,Nicolas Nagot,Clément Delmas
Temporary mechanical circulatory support (tMCS) using extracorporeal life support (ECLS), has been widely implemented in patients with cardiogenic shock (CS), although evidence regarding its efficacy and safety remains unclear. This lack of clarity has recently raised concerns about the role of tMCS in CS management. Conducting randomized controlled trials (RCTs) in the context of CS poses significant
-
Donor age and ischemic time in heart transplantation -implications for organ preservation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-02 Victoria Jernryd,Josef Stehlik,Carsten Metzsch,Lars H Lund,J Gustav Smith,Bodil Andersson,Raquel Perez,Johan Nilsson
INTRODUCTION The Organ Care System and Non-ischemic Heart Preservation methods have emerged as significant advancements in heart transplantation, designed to mitigate ischemic injury and extend preservation times. However, their high costs and logistical complexities necessitate strategic utilization. METHODS We evaluated data from 83,761 heart transplants registered in the International Society for
-
The Balance of Risks: Outcomes Associated with Mechanical Circulatory Support after Pediatric Heart Transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-02 Hari Tunuguntla,Aamir Jeewa
-
Early Single Center Experience with an Ex Vivo Organ Care System in Pediatric Heart Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-01 Cathlyn K Medina,Berk Aykut,Lauren E Parker,Neel K Prabhu,Lillian Kang,Ziv Beckerman,Jacob N Schroder,Douglas M Overbey,Joseph W Turek
Pediatric heart transplantation (HTx) faces challenges such as limited donor availability and the need for complex reconstructions, particularly in patients with congenital anomalies. Ex vivo perfusion offers a promising approach to minimize graft ischemic time and potentially expand the donor pool. We report our single-center experience using the TransMedics Organ Care System (OCS) for ex vivo perfusion
-
Utilization and Outcomes of Non-Intubated Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-30 Alice L Zhou,Maria R Jennings,Armaan F Akbar,Jessica M Ruck,Atharv Oak,Andrew Kalra,Emily L Larson,Alfred J Casillan,Jinny S Ha,Christian A Merlo,Errol L Bush
BACKGROUND Non-intubated extracorporeal membrane oxygenation (ECMO) has become an increasingly common method of support for patients with severe respiratory failure. Since data on its use as a bridge to lung transplant remain limited to single-center studies, we evaluated its use in a national cohort. METHODS Adult lung-only transplant recipients bridged with ECMO 5/4/2005-3/8/2023 in the United Network
-
Cancer as an independent mortality risk in chronic thromboembolic pulmonary hypertension. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-30 Junichi Nakamura,Ichizo Tsujino,Kohei Masaki,Kazuya Hosokawa,Kouta Funakoshi,Yu Taniguchi,Shiro Adachi,Takumi Inami,Jun Yamashita,Hitoshi Ogino,Masaru Hatano,Nobuhiro Yaoita,Nobutaka Ikeda,Hiroto Shimokawahara,Nobuhiro Tanabe,Kayoko Kubota,Ayako Shigeta,Yoshito Ogihara,Koshin Horimoto,Yoshihiro Dohi,Takashi Kawakami,Yuichi Tamura,Koichiro Tatsumi,Kohtaro Abe
BACKGROUND The management of chronic thromboembolic pulmonary hypertension (CTEPH) has advanced significantly in recent years, thereby improving patient prognosis. However, the impact of cancer on the outcomes of patients with CTEPH under current treatment remains unclear. This study aimed to investigate the prevalence of cancer in patients with CTEPH and determine how comorbid cancer affects their
-
The effect of rewarming ischemia on tissue transcriptome and metabolome signatures: a clinical observational study in lung transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-30 Jan Van Slambrouck,Shauni Loopmans,Elena Prisciandaro,Annalisa Barbarossa,Phéline Kortleven,Simon Feys,Christelle M Vandervelde,Xin Jin,Ismail Cenik,Karen Moermans,Steffen Fieuws,An-Lies Provoost,Anton Willems,Paul De Leyn,Hans Van Veer,Lieven Depypere,Yanina Jansen,Jacques Pirenne,Arne Neyrinck,Birgit Weynand,Bart Vanaudenaerde,Geert Carmeliet,Robin Vos,Dirk Van Raemdonck,Bart Ghesquière,Johan Van
BACKGROUND In lung transplantation (LuTx), various ischemic phases exist, yet the rewarming ischemia time (RIT) during implantation has often been overlooked. During RIT, lungs are deflated and exposed to the body temperature in the recipient's chest cavity. Our prior clinical findings demonstrated that prolonged RIT increases the risk of primary graft dysfunction. However, the molecular mechanisms
-
Volume calibration with cardiac MRI versus hypertonic saline for right ventricular pressure-volume loops with exercise: Impact on ventricular function and ventricular-vascular coupling. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-28 Farhan Raza,Chris G Lechuga,Oliver Wieben,Naomi C Chesler
BACKGROUND Right ventricular (RV) pressure-volume (PV) loops require postacquisition volume calibration by cardiac MRI (CMR) or hypertonic saline (HS). We defined the impact of these 2 volume calibration methods on rest-to-exercise ventricular contractility (end-systolic elastance: Ees), arterial afterload (Ea), and coupling (Ees/Ea). METHODS In a prospective study, 82 RV PV-loop datapoints (rest,
-
The lung transplant endobronchial biopsy: A forgotten specimen comes of age. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-28 Kieran Halloran,Robin Vos,Greg Snell,John R Greenland
Mucosal or endobronchial biopsies (EBB) are typically used in the diagnosis of directly visualized bronchial lesions, infection, and sarcoidosis, but their utility in the evaluation of lung transplant recipients is controversial. EBB represents an attractive alternative to transbronchial biopsy (TBB): EBB provides straightforward sampling of airway pathology with decreased complication rates due to
-
Lung transplant pathology: No longer through a glass darkly? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-28 Allan R Glanville
-
A novel cardioprotective perfusion protocol prevents functional decline during extended normothermic ex situ heart perfusion of porcine hearts. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-25 Mats T Vervoorn,Sjoerd van Tuijl,Elisa M Ballan,Selma E Kaffka Genaamd Dengler,Saskia C A de Jager,Joost P G Sluijter,Pieter A Doevendans,Niels P van der Kaaij
INTRODUCTION A common limitation to normothermic ex situ heart perfusion (ESHP) is functional decline. We previously designed a cardioprotective normothermic perfusion protocol, incorporating adenosine-lidocaine cardioplegia, subnormothermic reperfusion, pyruvate and methylprednisolone supplementation, and hemofiltration to prevent myocardial functional decline over 4 hours. In this study, we added
-
Identification and validation of a threshold for early posttransplant bronchoalveolar fluid hyaluronan that distinguishes lung recipients at risk for chronic lung allograft dysfunction. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-22 Jamie L Todd,Jeremy M Weber,Francine L Kelly,Andrew Nagler,Patrick McArthur,Lerin Eason,Jeeyon G Rim,Courtney W Frankel,John A Belperio,Marie Budev,Tereza Martinu,Kunal Patel,John M Reynolds,Pali D Shah,Lianne G Singer,Laurie D Snyder,Wayne Tsuang,S Sam Weigt,Megan L Neely,Scott M Palmer
BACKGROUND Few tools exist for the early identification of patients at risk for chronic lung allograft dysfunction (CLAD). We previously showed hyaluronan (HA), a matrix molecule that regulates lung inflammation and fibrosis, accumulates in bronchoalveolar lavage fluid (BALF) and blood in CLAD. We aimed to determine if early posttransplant HA elevations inform CLAD risk. METHODS HA was quantified in
-
iPhone or Blackberry? The unsure future of ex vivo lung perfusion: A commentary on ex vivo lung perfusion national trends and posttransplant outcomes. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-20 Gaurav Sharma,Michael E Jessen,Matthias Peltz
-
Impact of tacrolimus vs cyclosporine on chronic lung allograft dysfunction incidence and allograft survival in the International Society of Heart and Lung Transplantation registry. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-20 Michael P Combs,Krysta Walter,Haley Hixson,Elizabeth A Belloli,Matthew S Najor,Kevin M Chan,Andrew C Chang,Dennis M Lyu
BACKGROUND The ScanCLAD study reported a lower incidence of chronic lung allograft dysfunction (CLAD) with the use of once-daily tacrolimus vs twice-daily cyclosporine. Using the International Society for Heart and Lung Transplantation (ISHLT) Thoracic Organ Transplant (TTX) Registry data, we evaluated the hypothesis that tacrolimus is superior to cyclosporine in real-world clinical practice. METHODS
-
Impact of procurement methods on organ rejection in donation after circulatory death heart transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-20 Ye In Christopher Kwon,Elizabeth Bashian,Arman Kilic,Zubair A Hashmi
-
Severe primary graft dysfunction after heart transplantation-defining the subtypes. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-18 Sanjay Dutta,Peter S Macdonald
-
Bridging gaps in lung allocation: A data-driven approach to overcome biological disparities. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-18 Ankit Bharat
-
Sympathetic reinnervation in cardiac transplant recipients: Prevalence, time course, and association with long-term survival. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-18 Oliver J F Weiner,Moloy Das,Richard H Clayton,Janet M McComb,Alan Murray,Gareth Parry,Stephen W Lord
BACKGROUND Partial cardiac sympathetic reinnervation after cardiac transplant has been extensively investigated and evidenced. However, there have been no large-scale, long-term studies evaluating the prevalence, time-course, and association with long-term survival of sympathetic reinnervation of the heart. METHODS Cardiac transplant recipients (n = 232) were recruited from outpatient clinic at a single
-
Prognostic value of repeated peak oxygen uptake measurements in patients with a left ventricular assist device. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-18 William Herrik Nielsen,Mariusz K Szymanski,Kiran K Mirza,Linda W Van Laake,Thomas Schmidt,Darshan H Brahmbhatt,Filio Billia,Steven Hsu,Guy MacGowan,Djordje G Jakovljevic,Piergiuseppe Agostoni,Filippo Trombara,Ulrich P Jorde,Yogita Rochlani,Katrien Vandersmissen,Nils Reiss,Stuart D Russell,Bart Meyns,Finn Gustafsson
BACKGROUND Peak oxygen uptake (pVO2) predicts mortality in patients with heart failure on left ventricular assist device (LVAD) support. This follow-up of the PRO-VAD study examines the prognostic value of repeated pVO2 measurements during long-term follow-up. METHODS This multicenter follow-up study included patients from the original PRO-VAD cohort who performed a cardiopulmonary exercise test (CPET)
-
Lung re-transplantation for recipients with cystic fibrosis: Procedure choice and other considerations. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-17 Siddhartha G Kapnadak,Tijana Milinic,Kathleen J Ramos
-
Pathologist Interrater Reliability and Clinical Implications of Elevated Donor-Derived Cell-Free DNA beyond Heart Transplant Rejection. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-16 Aditya Mehta,Jason Goldberg,Pramita Bagchi,Charles Marboe,Keyur B Shah,Samer S Najjar,Steven Hsu,Maria E Rodrigo,Moon Kyoo Jang,Adam Cochrane,Inna F Tchoukina,Hyesik Kong,Brendan J Lohmar,Erick Mcnair,Hannah A Valantine,Sean Agbor-Enoh,Gerald J Berry,Palak Shah,
BACKGROUND There is significant variability amongst pathologists in the histopathological interpretation of the endomyocardial biopsy (EMB) for acute cellular rejection (ACR) and assessment of variability in the interpretation of antibody-mediated rejection (AMR) has not been reported. In contemporary practice, the strategy of allograft surveillance with donor-derived cell-free DNA (dd-cfDNA) as compared
-
Diagnostic alignment to optimize inter-rater reliability among lung transplant pathologists. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-13 Elizabeth N Pavlisko,Megan L Neely,Kathryn A Wikenheiser-Brokamp,Gregory A Fishbein,Leslie Litzky,Carol F Farver,Prodipto Pal,Mai He,Peter B Illei,Charuhas Deshpande,Mark A Robien,Jerry Kirchner,Courtney W Frankel,Jason E Lang,John A Belperio,Scott M Palmer,Stuart C Sweet,
BACKGROUND Poor agreement among lung transplant (LTx) pathologists has been reported in the assessment of rejection. In addition to acute rejection (AR) and lymphocytic bronchiolitis (LB), acute lung injury (ALI) and organizing pneumonia (OP) were recently identified as histopathologic risk factors for chronic lung allograft dysfunction (CLAD). Therefore, maximizing inter-rater reliability (IRR) for
-
Limitations of the inotrope score use as a measure of primary graft dysfunction. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-11 David M Kaye,Christina E Kure,Andreas Wallinder,David C McGiffin
Allograft dysfunction is the major cause of early morbidity and mortality following cardiac transplantation. Poor graft function can be secondary to transplant complications or, when no identifiable cause is present, primary graft dysfunction (PGD). To standardize the definition of PGD, a consensus conference was convened which produced a document that defines severity categories and criteria for assessing
-
Medium to long-term ventricular assist device support in adults with congenital heart disease. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-11 Ryan D Byrne,William C Frankel,Ajith Nair,Hari Tunuguntla,Swati Choudhry,Iki Adachi,Edward J Hickey,Andrew B Civitello,Christopher R Broda
Heart failure is the leading cause of morbidity and mortality in adults with congenital heart disease. However, for many in this population, heart transplantation is not possible or requires longer wait times, necessitating prolonged circulatory support. The medium to long-term durable ventricular assist device therapy provides a possible solution. We analyzed outcomes of 9 patients with congenital
-
A supply-based scoring approach to account for biological disadvantages in accessing lung transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-10 Johnie Rose,Paul R Gunsalus,Carli J Lehr,Mark F Swiler,Jarrod E Dalton,Maryam Valapour
BACKGROUND The lung Composite Allocation Score (CAS) accounts separately for biological disadvantages stemming from candidate blood type and height using consensus-derived heuristics, which do not reflect the true supply of compatible organs available to candidates with specific combinations of blood type and height. Here, we develop an alternative CAS biological disadvantages subscore using a novel
-
Navigating between management of pulmonary arterial hypertension and cardiometabolic and pulmonary comorbidities. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-10 Hakim Ghani,Joanna Pepke-Zaba
-
Impact of type of mechanical circulatory support before transplant on postorthotopic heart transplantation infections. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-10 Caitlin A Trottier,Audrey Martino,Meghan I Short,Angie Mae Rodday,Andrew M Strand,Michael S Kiernan,Amanda R Vest,David R Snydman,Jennifer K Chow
BACKGROUND Infections after orthotopic heart transplantation (OHT) cause significant morbidity and mortality. Concurrent with increased pre-OHT temporary mechanical circulatory support (MCS), there have been recent concerns of a perceived increase in infections post-OHT. We examined the association between pre-OHT temporary versus durable MCS and post-OHT infection. METHODS We performed a single-center
-
Loss of right ventricular outflow function in pulmonary hypertension. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-10 Bruno R Brito da Rocha,Athiththan Yogeswaran,Bálint K Lakatos,Alexandra Fábián,Henning Gall,Hossein A Ghofrani,Nils C Kremer,Simon Schäfer,Werner Seeger,Daniel Zedler,Selin Yildiz,Zvonimir A Rako,Attila Kovács,Khodr Tello
Right ventricular outflow tract (RVOT) function is not systematically quantified by three-dimensional (3D) echocardiography. We tested the hypothesis that loss of RVOT function in pulmonary hypertension (PH) is related to disease severity independently of other echocardiographic parameters. In this observational study, patients with PH, disease controls, and a matched healthy control group underwent
-
ISHLT consensus statement on the perioperative use of ECLS in lung transplantation: Part II: Intraoperative considerations. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-09 Archer Kilbourne Martin,Olaf Mercier,Ashley Virginia Fritz,Theresa A Gelzinis,Konrad Hoetzenecker,Sandra Lindstedt,Nandor Marczin,Barbara J Wilkey,Marc Schecter,Haifa Lyster,Melissa Sanchez,James Walsh,Orla Morrissey,Bronwyn Levvey,Caroline Landry,Siavosh Saatee,Sakhee Kotecha,Juergen Behr,Jasleen Kukreja,Göran Dellgren,Julien Fessler,Brandi Bottiger,Keith Wille,Kavita Dave,Basil S Nasir,David Gomez-De-Antonio
The use of extracorporeal life support (ECLS) throughout the perioperative phase of lung transplantation requires nuanced planning and execution by an integrated team of multidisciplinary experts. To date, no multidisciplinary consensus document has examined the perioperative considerations of how to best manage these patients. To address this challenge, this perioperative utilization of ECLS in lung
-
Early stroke following durable left ventricular assist device (LVAD) implantation: An analysis of the Society of Thoracic Surgeons Intermacs National Database. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-09 Ezequiel J Molina,Daniel Goldstein,Ryan S Cantor,Manreet K Kanwar,Dan Meyer,Ulrich Jorde,Omar Saeed,Katherine Wood,Rama Raju Rudraraju,Seth Lewis,James K Kirklin,Francis D Pagani,Arman Kilic
BACKGROUND Stroke remains a devastating complication of durable left ventricular assist device (LVAD) therapy. This study evaluated the incidence and risk factors for early stroke within 7 days following LVAD implantation investigating both traditional pre-implant and new intraoperative variables collected by The Society of Thoracic Surgeons (STS) Intermacs National Database. METHODS STS Intermacs
-
Outcomes of donation after circulatory death (DCD) and ex-vivo lung perfusion (EVLP) lung transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-09 Selena S Li,Masaki Funamoto,Ruby Singh,Seyed A Rabi,Antonia Kreso,Eriberto Michel,Nathaniel B Langer,Asishana A Osho
BACKGROUND Donation after circulatory death (DCD) and ex-vivo lung perfusion (EVLP) have been adopted to expand the donor pool in lung transplantation, but outcomes data have been conflicting. This study explores outcomes of DCD and EVLP lung transplantation in the modern era. METHODS The United Network for Organ Sharing database was queried for adult lung transplants from January 1, 2015 to March
-
Recurrence of pulmonary arterial hypertension 32 months after bilateral lung transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-05 Octavia Kurn,Caroline Patterson,John Cannon,Karen Sheares,Dolores Taboada Buasso,Asfandyar Yousuf,Katherine Bunclark
-
A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-05 Thomas M Cascino,Sandeep Sahay,Victor M Moles,Vallerie V McLaughlin
Despite increasing therapeutic options and evolving treatment strategies, including targeting 3 therapeutic pathways, in the management of pulmonary arterial hypertension (PAH), morbidity and mortality have remained unacceptably high. Sotatercept is a first-in-class, novel activin signaling inhibitor approved for treating PAH based on evolving efficacy and safety evidence. This state-of-the-art review
-
A perspective on the added value of red blood cells during cardiac hypothermic oxygenated perfusion. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-05 Mats T Vervoorn,Elisa M Ballan,Selma E Kaffka Genaamd Dengler,Veronique M F Meijborg,Saskia C A de Jager,Richard Van Wijk,Niels P van der Kaaij
Hypothermic oxygenated perfusion (HOPE) is an emerging technique for donor heart preservation that is currently being studied in multiple clinical trials with promising results. When compared to HOPE for other organs, cardiac protocols involve red blood cell (RBC) supplementation, despite absence of comparative evidence for its benefits. In this perspective paper, we discuss the pros and cons of the
-
Loss of Nr4a1 ameliorates endothelial cell injury and vascular leakage in lung transplantation from circulatory-death donor. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-05 Shinichi Kawana,Mikio Okazaki,Tomohisa Sakaue,Kohei Hashimoto,Kentaro Nakata,Haruki Choshi,Shin Tanaka,Kentaroh Miyoshi,Shinji Ohtani,Toshiaki Ohara,Seiichiro Sugimoto,Akihiro Matsukawa,Shinichi Toyooka
BACKGROUND Ischemia-reperfusion injury (IRI) stands as a major trigger for primary graft dysfunction (PGD) in lung transplantation (LTx). Especially in LTx from donation after cardiac death (DCD), effective control of IRI following warm ischemia (WIRI) is crucial to prevent PGD. This study aimed to identify the key factors affecting WIRI in LTx from DCD. METHODS Previously reported RNA-sequencing dataset
-
The outcome of restrictive cardiac allograft physiology in severe coronary allograft vasculopathy. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-05 Masaki Tsuji,Jignesh K Patel,Michelle M Kittleson,David H Chang,Evan P Kransdorf,Andriana P Nikolova,Lily K Stern,Nayana Bhatnagar,Jon A Kobashigawa
BACKGROUND Microvascular dysfunction after heart transplantation leads to restrictive cardiac allograft physiology (RCP), which is classified as severe coronary allograft vasculopathy (CAV); however, the prognosis of RCP remains unclear. Therefore, in this study, we aimed to elucidate the prognosis of RCP in comparison with that of severe angiographic CAV. METHODS We assessed 116 patients with severe
-
Detailed cellular and spatial characterization of chronic lung allograft dysfunction using imaging mass cytometry. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-03 Benjamin Renaud-Picard,Sajad Moshkelgosha,Gregory Berra,May Cheung,David Hwang,David Hedley,Stephen Juvet,Tereza Martinu
Long-term survival after lung transplantation remains limited by chronic lung allograft dysfunction (CLAD), with 2 main phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). We aimed to assess CLAD lung allografts using imaging mass cytometry (IMC), a high dimensional tissue imaging system allowing a multiparametric in situ exploration at a single cell level
-
Simultaneous heart and kidney transplantation for high-risk candidates on extracorporeal life support: Don't judge a book by its cover. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-03 Mickaël Lescroart,Guillaume Coutance
-
Context matters: Neighborhood health affects heart transplant outcomes even at high-volume centers. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-03 Jaya Batra,Ersilia M DeFilippis
-
Defining direct and indirect right ventricular unloading. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-03 Jamel Ortoleva,Dominic V Pisano
-
Outcomes of controlled DCDD lung transplantation after thoraco-abdominal vs abdominal normothermic regional perfusion: The Spanish experience. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-09-30 Anna Minasyan,Mercedes de la Torre,Joel Rosado Rodriguez,Alberto Jauregui Abularach,Alejandra Romero Román,Nuria Novoa Valentin,Ivan Martínez Serna,Pablo Gámez García,Alilis Fontana,Gabriel Sales Badia,Francisco Javier González García,Angel Salvatierra Velazquez,Loreto Berjon,Roberto Mons Lera,Pedro Rodríguez Suarez,Elisabeth Coll,Eduardo Miñambres,Beatriz Domínguez-Gil,Jose Luis Campo-Cañaveral de
BACKGROUND Thoraco-abdominal normothermic regional perfusion (TA-NRP) has emerged as a strategy for evaluating and recovering the heart in controlled donation after the circulatory determination of death (cDCDD). However, its impact on lung grafts remains largely unknown. We aimed to assess the impact of TA-NRP on the outcomes of recipients of cDCDD lungs. METHODS This is a retrospective, multicenter
-
The search continues: Investigating potential biomarkers to predict cardiac allograft function from donation after circulatory death donors. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-09-29 Yashutosh Joshi,Peter S Macdonald
-
Extracorporeal membrane oxygenation as a bridge to thoracic multiorgan transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-09-27 Elbert E Heng,Aravind Krishnan,Stefan Elde,Alyssa Garrison,Moeed Fawad,Chawannuch Ruaengsri,Yasuhiro Shudo,Brandon A Guenthart,Y Joseph Woo,John W MacArthur
BACKGROUND Extracorporeal membrane oxygenation (ECMO) has emerged as a crucial tool in the care of patients with multiorgan failure and is increasingly utilized as a bridge to transplantation. While data on ECMO as a bridge to isolated heart and lung transplantation have been described, our emerging experience with ECMO as a bridge to thoracic multiorgan transplantation is not yet well understood.
-
Authors' Response to Comment and Opinion. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-09-26 Anthony P Carnicelli,Jennifer Cowger,Ryan J Tedford,Manreet Kanwar
-
Outcomes of single vs double lung retransplantation in patients with cystic fibrosis. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-09-18 Emily L Larson,Albert Leng,Jessica M Ruck,Alfred J Casillan,Alice L Zhou,Jinny S Ha,Pali D Shah,Natalie E West,Christian A Merlo,Errol L Bush
BACKGROUND Patients requiring lung transplant for cystic fibrosis (CF) may require retransplant due to limited graft survival and otherwise excellent life expectancy. Optimal transplant strategy for this population, including single vs double lung retransplant, has not been established. METHODS We performed a retrospective analysis of the United Network for Organ Sharing/Organ Procurement and Transplant
-
Impact of routine extracorporeal cardiopulmonary resuscitation service on the availability of donor organs. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-09-16 Jana Smalcova,Petra Krupickova,Eva Pokorna,Ondrej Franek,Michal Huptych,Petra Kavalkova,Martin Balik,Jan Malik,Ondrej Smid,Eva Svobodova,Roman Keleman,Jan Belohlavek
BACKGROUND In refractory cardiac arrest, extracorporeal cardiopulmonary resuscitation may increase the survival chance. However, in cases of unsuccessful treatment, extracorporeal cardiopulmonary resuscitation may additionally provide an important source of organ donors. Therefore, we hypothesized that implementing extracorporeal cardiopulmonary resuscitation service into a high-volume cardiac arrest